| # | Title | Journal | Year | Citations |
|---|
| 1 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 | JAMA Oncology | 2017 | 4,254 |
| 2 | Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States | JAMA Oncology | 2017 | 2,289 |
| 3 | The Global Burden of Cancer 2013 | JAMA Oncology | 2015 | 2,269 |
| 4 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 | JAMA Oncology | 2019 | 1,691 |
| 5 | Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors | JAMA Oncology | 2018 | 1,625 |
| 6 | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level | JAMA Oncology | 2017 | 1,448 |
| 7 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer | JAMA Oncology | 2018 | 1,350 |
| 8 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 | JAMA Oncology | 2018 | 1,260 |
| 9 | Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma | JAMA Oncology | 2016 | 1,192 |
| 10 | SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China | JAMA Oncology | 2020 | 862 |
| 11 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma | JAMA Oncology | 2020 | 805 |
| 12 | Using the National Cancer Database for Outcomes Research | JAMA Oncology | 2017 | 786 |
| 13 | Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer | JAMA Oncology | 2018 | 755 |
| 14 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens | JAMA Oncology | 2018 | 753 |
| 15 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma | JAMA Oncology | 2017 | 750 |
| 16 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
| 17 | Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer | JAMA Oncology | 2018 | 735 |
| 18 | Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 | JAMA Oncology | 2022 | 719 |
| 19 | Association of the Extent of Resection With Survival in Glioblastoma | JAMA Oncology | 2016 | 710 |
| 20 | Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer | JAMA Oncology | 2020 | 696 |
| 21 | Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer | JAMA Oncology | 2016 | 693 |
| 22 | Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer | JAMA Oncology | 2019 | 670 |
| 23 | Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors | JAMA Oncology | 2016 | 667 |
| 24 | A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer | JAMA Oncology | 2017 | 658 |
| 25 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer | JAMA Oncology | 2020 | 611 |
| 26 | HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma | JAMA Oncology | 2017 | 608 |
| 27 | Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer | JAMA Oncology | 2016 | 600 |
| 28 | Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer | JAMA Oncology | 2018 | 599 |
| 29 | Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | JAMA Oncology | 2015 | 581 |
| 30 | Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue | JAMA Oncology | 2017 | 580 |
| 31 | Inherited Mutations in Women With Ovarian Carcinoma | JAMA Oncology | 2016 | 576 |
| 32 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | JAMA Oncology | 2020 | 572 |
| 33 | Role of Local Radiation Therapy in Cancer Immunotherapy | JAMA Oncology | 2015 | 570 |
| 34 | Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy | JAMA Oncology | 2018 | 567 |
| 35 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer | JAMA Oncology | 2019 | 557 |
| 36 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer | JAMA Oncology | 2017 | 555 |
| 37 | Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer | JAMA Oncology | 2015 | 552 |
| 38 | Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer | JAMA Oncology | 2017 | 544 |
| 39 | Estimating Survival in Patients With Lung Cancer and Brain Metastases | JAMA Oncology | 2017 | 543 |
| 40 | Hereditary Diffuse Gastric Cancer Syndrome | JAMA Oncology | 2015 | 540 |
| 41 | Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer | JAMA Oncology | 2019 | 538 |
| 42 | Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer | JAMA Oncology | 2016 | 535 |
| 43 | Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders | JAMA Oncology | 2016 | 534 |
| 44 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials | JAMA Oncology | 2019 | 526 |
| 45 | Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 | JAMA Oncology | 2015 | 523 |
| 46 | Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib | JAMA Oncology | 2018 | 522 |
| 47 | Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer | JAMA Oncology | 2016 | 516 |
| 48 | Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer | JAMA Oncology | 2017 | 510 |
| 49 | Fusobacterium nucleatumand T Cells in Colorectal Carcinoma | JAMA Oncology | 2015 | 498 |
| 50 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | JAMA Oncology | 2015 | 498 |
